Nominations open for experts to join COVAX group advising on COVID-19 vaccine candidates

Jodie Rogers
COVAX: CEPI's response to COVID-19
Please note the deadline for applications (17 July 2020) has now passed.


CEPI, Gavi, and WHO have launched the COVID-19 Vaccine Global Access Facility (COVAX), part of the ACT Accelerator, working as an end-to-end solution to ensure equitable access to COVID-19 vaccines for all countries, at all levels of development, that wish to participate.

COVAX will harness the strengths of CEPI, Gavi and WHO, to accelerate development, manufacture, stockpiling, procurement, and fair allocation of up to 2 billion doses of a licensed vaccine by the end of 2021 — thereby ending the acute phase of the pandemic as quickly as possible, saving millions of lives and transforming the economic prospects of societies around the world.

COVAX Independent Product Group now open for nominations

We are currently seeking experts to join the COVAX Independent Product Group.

Set up by CEPI and Gavi, the group will work as a diverse and globally representative committee to provide an independent process to advise the COVAX Pillar and the COVAX Facility—part of COVAX which will pool investments from participating countries to secure large volumes of vaccine to be allocated globally—on the vaccine candidates likely to meet threshold criteria for purchase by the Facility, and subsequently, whether those criteria are met.

Working as part of the COVAX Development and Manufacturing workstream, which is tasked with R&D and manufacturing investment decision making for the COVAX portfolio of vaccine candidates and enabling sciences activities, the Independent Product Group will review the data and information on all COVID-19 candidate vaccines proposed for procurement by the COVAX Facility and provide recommendations to the COVAX facility to inform their decisions.

We are currently looking for 5-7 experts to join the COVAX Independent Product Group, with independent expertise in the following areas sought:

- Coronavirus vaccines and/or COVID-19 vaccines

- Animal models and assays for vaccine evaluation

- Clinical evaluation of vaccines including vaccine evaluation in large randomised clinical trials

- Regulatory expertise in vaccine evaluation

- Vaccine manufacturing and GMP issues

- Epidemiology/public health expertise

- Expertise in immunization programmes and service delivery

- Vaccine safety evaluation and monitoring


The deadline for submission of nominations (17 July 2020) has now passed.
Further information and details on how to apply is available here.
Act Now. Act Together. Act to end COVID-19.